Indications
Fungi are eukaryotic organisms that exist in all environments worldwide. They exist in many forms, ranging from visible fungi, such as mushrooms, to microscopic yeasts and molds. While most fungi do not play a significant role in human disease, there are several hundred fungi that do, resulting in fungal infection or disease. Fungal infections (mycoses) range from common benign infections like 'jock itch' to severe, life-threatening illnesses such as cryptococcal meningitis. The term 'antifungals' encompasses all chemical compounds, pharmacologic agents, and natural products used to treat mycoses.
Clinically, fungal infections are best categorized first by the site and extent of the infection, then by the route of acquisition, and finally, by the virulence of the causative organism. These classifications are essential when determining the most effective treatment regimen for a particular mycosis. Mycoses are classified as local (superficial, cutaneous, subcutaneous) or systemic (deep, bloodborne). The acquisition of the fungal infection can occur through either an exogenous (airborne/inhalation, cutaneous exposure, or percutaneous inoculation) or an endogenous process (normal flora or reactivation of an existing infection). The virulence of the organism is classified as either a primary infection (a disease arising in a healthy host) or an opportunistic infection (a disease arising in human hosts with a compromised immune system or other defenses).[1]
Antifungal drugs represent a pharmacologically diverse group of drugs that are crucial components in the modern medical management of mycoses. While antimycotic pharmacology has advanced significantly, particularly over the last 3 decades, common invasive fungal infections still carry a high mortality rate: Candida albicans (20% to 40% mortality), Aspergillus fumigatus (50% to 90%), and Cryptococcus neoformans (20% to 70%).[2][3]
Amphotericin B deoxycholate, a polyene antibiotic, was the first antimycotic agent introduced in 1958 to treat systemic mycoses. While this drug is an effective agent, the demand for other efficacious topical, oral, and intravenous agents was apparent. Griseofulvin was introduced in 1959, representing the second class of antifungals. The next significant introduction would not occur until 1971 when the antimetabolite drug flucytosine entered the market. Azoles first became available in 1973 with the arrival of clotrimazole; additional azoles that have the pharmaceutical industry has rolled out over the past 5 decades: miconazole (1979), ketoconazole (1981), fluconazole (1990), itraconazole (1992), voriconazole (2002), posaconazole (2006), and most recently isavuconazonium (2015).[4] Terbinafine, an allylamine antifungal, was approved by the FDA in 1996 and has indications for treating local, non-systemic fungal infections. The next breakthrough in systemic therapy would be based on amphotericin B lipid formulations, which have more favorable adverse effect profiles.
In 2021, the FDA approved ibrexafungerp, a triterpenoid fungicidal agent, making it the first oral non-azole treatment option for vulvovaginal candidiasis.[5] Following lipid formulations of azoles, a new class of antifungal agents that are highly effective in treating some systemic mycoses, is the recently developed echinocandin class. While the echinocandins demonstrate less renal toxicity than amphotericin B, they cause significant hepatotoxicity and are more expensive than azoles; this effectively relegates this class to second- or third-line agents. Rezafungin was approved by the FDA in 2023.[6][7] Mechanistically, antifungal agents are diverse, yet due to the alarming and rapid increase in drug-resistant systemic fungal infections, new agents are more necessary than ever.[8][9][10][11] This discussion will focus on the currently available antifungal agents.[12][13][14][15]
Common, medically relevant fungal infections include, but are not limited to, the conditions and causative organisms listed below.[16][17][18][19]
- Aspergillosis - Aspergillus fumigatus, A. flavus
- Blastomycosis - Blastomyces dermatitidis
- Candidiasis - Candida albicans, C glabrata, C krusei, C parasilosis, C tropicalis
- Chromoblastomycosis (Chromomycosis) - Cladosporium carrionii, Phialophora verrucosa, Fonsecaea pedrosoi
- Coccidioidomycosis - Coccidioides imitis, C posadasii
- Cryptococcosis - Cryptococcus neoformans, C gattii
- Dermatophytosis (Tinea) - Microsporum spp, Epidermophyton spp, Trichophyton spp
- Fusariosis - Fusarium oxysporum, F proliferatum, F verticillioides
- Histoplasmosis - Histoplasma capsulatum
- Mucormycosis (Zygomycosis) - Mucor spp, Rhizopus spp
- Paracoccidioidomycosis - Paracoccidioides brasiliensis
- Pneumocystis pneumonia - Pneumocystis jirovecii (formerly called P. carinii)*
- *While this is an essential and prevalent fungal disease, it is not treated with typical antifungal agents.
- Sporotrichosis - Sporothrix schenckii
- Tinea (Pityriasis) Versicolor - Malassezia furfur (also called Pityrosporum orbiculare), M globosa
Antifungal Drug Classification and Common Specific Drugs
- Loss of cell membrane integrity:
- Loss of cell wall integrity:
- Echinocandins: anidulafungin, caspofungin, micafungin, rezafungin [6]
- Mitotic inhibitors: griseofulvin
- Antimetabolites: flucytosine
- Ciclopirox
- Quinoline derivatives: iodoquinol, clioquinol
- Potassium iodide: saturated solution of potassium iodide (SSKI)
- Zinc pyrithione
- Triterpenoid antifungal agent: Ibrexafungerp [21]
Indications
Various antifungal agents are indicated for the situations discussed below.[22][23][24][25]
Amphotericin B deoxycholate (AMB-d) is FDA indicated for treating life-threatening or potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, and mucormycosis. AMB-d is also approved for treating the parasitic disease American mucocutaneous leishmaniasis. AMB-d has an off-label use for esophageal candidiasis (both HIV infected and non-HIV-infected adults and adolescents; HIV-exposed and or infected infants and children), fluconazole-refractory oropharyngeal candidiasis, candidal endophthalmitis, candidal urinary tract infections, visceral leishmaniasis, and ophthalmic aspergillosis.
Liposomal amphotericin B (L-AMB) has FDA approval for treating systemic aspergillosis, candidiasis, and cryptococcosis in patients with renal impairment and those refractory to AMB-d therapy. Additionally, L-AMB is an empiric antifungal therapy in patients with febrile neutropenia or HIV with cryptococcal meningitis. Visceral leishmaniasis is a parasitic infection that is also treated with this agent. L-AMB has extensive off-label usage for patients infected or exposed to HIV, including candidiasis, coccidioidomycosis, cryptococcosis, and histoplasmosis.[26][27][28][29]
Amphotericin B lipid complex (ABLC), like L-AMB, is indicated for treating invasive mycoses in patients unable to tolerate AMB-d. Off-label use of ABLC is an indicated agent in HIV infected patients with coccidioidomycosis, cryptococcal meningitis, and histoplasmosis; empiric therapy for candidiasis and neutropenic fever; and in the treatment of the parasitic infection, visceral leishmaniasis.[30][31][32][33]
Nystatin has been approved as an oral "swish-and-swallow" suspension for treating cutaneous, mucocutaneous, and oral Candida infections. Topically, nystatin has been approved for treating mucocutaneous and cutaneous infections with Candida spp (most commonly C. albicans).
Ketoconazole, when applied topically, has been approved for the treatment of tinea corporis, tinea cruris, tinea pedis, tinea versicolor, cutaneous candidiasis, and seborrheic dermatitis. Off-label, topical ketoconazole is used to treat several oral candidal pathologies, including chronic mucocutaneous candidiasis and oral thrush. Ketoconazole is also a systemic agent, approved for treating blastomycosis, coccidioidomycosis, chromomycosis, histoplasmosis, and paracoccidioidomycosis. Off-label oral ketoconazole treatment is used to treat Cushing syndrome and prostate cancer.[34][35]
Miconazole in its topical form is approved to treat cutaneous and mucocutaneous mycoses, particularly vulvovaginal candidiasis. Oral formulations of miconazole are indicated for the treatment of oropharyngeal candidiasis.
Clotrimazole, in topical forms, is approved to treat tinea corporis, tinea pedis, tinea versicolor, cutaneous candidiasis, and vaginal yeast infections. Oral clotrimazole is indicated for the treatment of oropharyngeal candidiasis.
Itraconazole is an oral drug approved to treat aspergillosis (pulmonary and extrapulmonary), blastomycosis (pulmonary and extrapulmonary), and histoplasmosis (systemic/disseminated not involving the CNS, cavitary pulmonary histoplasmosis) in patients who are immunocompromised and immunocompetent. In immunocompetent patients, this drug is also approved for the treatment of oropharyngeal candidiasis, esophageal candidiasis, and onychomycosis (involving the toenails or fingernails).
Fluconazole indications include the treatment of esophageal, oropharyngeal, peritoneal, urinary tract, and vaginal candidiasis. Fluconazole may also help treat systemic fungal infections, including candidemia, candida pneumonia, and cryptococcal meningitis. Fluconazole serves as a first-line agent in prophylaxis for mycoses in allogeneic hematopoietic stem cell transplant patients. Off-label, fluconazole has a variety of applications, including blastomycosis, empiric antifungal therapy in non-neutropenic ICU patients, Candida prophylaxis (in ICU patients with a high risk of invasive Candida spp and transplant patients), and tinea.[36]
Voriconazole has approval for the following indications: invasive aspergillosis, candidemia in patients without neutropenia, esophageal candidiasis, and disseminated candidiasis. This drug also treats life-threatening mycoses caused by fungi, such as Fusarium spp Off-label uses for voriconazole are primarily aimed at prophylactic and suppressive therapy for fungal infections, including but not limited to aspergillosis, candidiasis, hematopoietic stem cell transplant patients with or without graft-versus-host disease, acute myelogenous leukemia, and empiric therapy in neutropenic fever.
Isavuconazole is approved to treat invasive aspergillosis and invasive mucormycosis in adult populations.
Posaconazole is approved for prophylaxis of both invasive aspergillosis and invasive candidiasis. Additionally, it is used to treat oropharyngeal candidiasis, typically for patient populations refractory to treatment with fluconazole and itraconazole.
Terbinafine is approved for both topical and systemic (oral) use. Topical terbinafine is approved to treat tinea pedis, cruris, and corporis. When administered orally, this drug is indicated for the systemic treatment of onychomycosis (tinea unguium) and tinea capitis. Common off-label uses of oral formulations include treating tinea (cruris, corporis, penis, and manuum) as well as lymphocutaneous and cutaneous sporotrichosis.
Anidulafungin is an echinocandin that is administered intravenously only. This drug has been approved for the treatment of Candida spp infections (esophageal candidiasis, candidemia, Candida spp peritonitis, and intrabdominal abscesses when Candida spp is grown in culture or the suspected organism).
Caspofungin is only administered intravenously. This agent is approved for treating invasive aspergillosis in patient populations refractory to amphotericin B and itraconazole. Caspofungin has also received approval for treating Candida spp infections (candidemia, esophageal, intra-abdominal abscess, peritonitis, and empiric therapy in patients with neutropenia). Off-label, this agent is used as an adjunct in the treatment of other severe Candida spp infections not listed above.
Micafungin is also approved for intravenous administration to treat esophageal candidiasis and for the prophylaxis of Candida spp infections, including candidemia, Candida spp peritonitis, Candida spp abscesses, and disseminated candidiasis.
Griseofulvin is only approved as a systemic (oral) agent. This drug is indicated for treating dermatophytoses of the skin, hair, and nails, which are severe or refractory to topical therapy. Specifically, this drug treats tinea (corporis, pedis, cruris, barbae, capitis, and unguium).
Flucytosine has been approved as an adjunct antifungal agent for treating systemic infections caused by Candida spp or Cryptococcus spp infections. Off-label, flucytosine is administered to treat pediatric endocarditis caused by Aspergillus spp; however, other antifungal agents, such as amphotericin B or voriconazole, are preferred for Aspergillus infections.
Ciclopirox is FDA-approved for the topical treatment of tinea corporis, tinea pedis, tinea cruris, tinea unguium (onychomycosis), tinea (pityriasis) versicolor, and Candida spp infection with moniliasis.
Iodoquinol (discontinued in the USA) was a topical agent approved for treating tinea capitis, tinea cruris, tinea corporis, tinea pedis, moniliasis, and candidal intertrigo.
Clioquinol is a combination product with hydrocortisone (availability in the U.S. is unclear). This combination topical agent was approved to treat the same spectrum of dermatoses as iodoquinol: tinea capitis, tinea cruris, tinea corporis, tinea pedis, moniliasis, and candidal intertrigo.
Potassium iodide, formulated as a saturated solution of potassium iodide (SSKI), has no official antifungal approvals, but is used in the off-label treatment of both cutaneous and lymphocutaneous sporotrichosis.
Zinc pyrithione is not officially approved for antifungal purposes but has been utilized as primary or adjunct therapy in the treatment of mycoses leading to hyperkeratotic skin conditions. A common off-label use is in treating tinea (pityriasis) versicolor.
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Polyene antifungals (eg, amphotericin B) bind to ergosterol, a steroid-alcohol unique to fungi. The polyene-ergosterol complex creates pores in the fungal cell membrane, ultimately leading to electrolyte leakage, cell lysis, and cell death.[37]
Azole (eg, miconazole) antifungal compounds are non-competitive inhibitors of the fungal enzyme lanosterol 14-α-demethylase, a rate-limiting enzyme in the fungal biosynthetic ergosterol pathway. This action destabilizes the fungal cell membrane, leading to leakage of cell content, lysis, and ultimately, cell death.[38]
Allylamines (eg, terbinafine) inhibit the rate-limiting enzyme squalene epoxidase, which is responsible for synthesizing precursors to ergosterol. This type of drug is another antifungal compound whose mechanism of action is the loss of cell membrane integrity.[39]
Echinocandins (eg, caspofungin) inhibit the fungal β-(1,3)-D-glucan synthase, which is the enzyme responsible for synthesizing β-(1,3)-D-glucan, a key component of fungal cell walls. Losing this cell wall component leads to osmotic instability and cell death.[7]
Griseofulvin is a mitotic inhibitor that binds to polymerized fungal microtubules, thereby inhibiting depolymerization and leading to the failure of fungal cell replication.[40]
Flucytosine is an antimetabolite compound absorbed into fungal cells via cytosine permease. Within the fungal cell, flucytosine gets converted to 5-fluorouracil, which interferes with fungal RNA biosynthesis.[41]
Ciclopirox has a poorly understood mechanism of action but is believed to interfere with the structural integrity of the fungal cell membrane.[42]
Quinoline antifungal (eg, clioquinol) compound derivatives also have a mechanism of action that is poorly understood.
Potassium iodide exerts its effects directly on Sporothrix spp, yet the exact mechanism of action remains unproven. Leading theories suggest that human polymorphonuclear cells convert potassium iodide to iodine through the action of myeloperoxidase. Iodine inhibits fungal germination and reduces structural integrity through the intracytosolic destruction of structural components.[43]
Zinc pyrithione has a poorly understood mechanism of action against fungi. Still, leading theories suggest that this agent modifies fungal cellular membrane transport, decreasing the concentrations of critical metabolic substrates, inhibiting protein synthesis, and limiting ATP production.[44] These metabolic changes are likely due to increased intracellular copper and iron-sulfur cluster formation, which leads to protein damage.[45]
Administration
Amphotericin B has several formulations, including amphotericin B deoxycholate (d-AMB, or AMB-d), liposomal amphotericin B (L-AMB), amphotericin B lipid complex (ABLC), and amphotericin B colloidal dispersion (ABCD; not available in the United States). All approved indications require intravenous administration. Off-label administration of AMB-d is also given intraventricularly and as an irrigation solution.
Nystatin, the other polyene drug, is only approved for topical and oral "swish-and-swallow' applications. Nystatin is available as a powder, cream, and oral solution.
Azole preparations for systemic azole antifungals include tablets, capsules, oral, and IV solutions. Azole drugs for local or topical use include powders, creams, ointments, gels, shampoos, and lozenges.
Terbinafine, a member of the allylamine class of antifungals, can be administered topically or orally, depending on whether the fungal infection is local or systemic.
Caspofungin, anidulafungin, and micafungin, the 3 primary echinocandin medications, are all given intravenously as a reconstituted solution.
Griseofulvin is administered orally as a tablet or suspension and should be taken with a fatty meal to enhance absorption.
Flucytosine, also commonly known as 5-fluorocytosine, is almost always administered intravenously as a combination therapy with amphotericin B to treat mycoses.
Ciclopirox is approved for topical use only, not intracavitary or ophthalmic applications. This drug is available as a compounded gel, cream, lacquer, shampoo, and suspension.
Quinolines, iodoquinol, and clioquinol had approval for topical administration. Clioquinol is combined with hydrocortisone in a compounded cream.
Potassium iodide is most commonly administered topically as a saturated solution of potassium iodide (SSKI).
Zinc pyrithione, a compound used to treat topical fungal infections, is applied topically as a shampoo, a solid soap-like bar, or a non-shampoo liquid.
Adverse Effects
The systemic polyene antifungal amphotericin B (formulated as AMB-d, L-AMB, ABLC, and ABCD) has the potential for severe adverse reactions. AMB-d therapy carries the risk of hypotension, chills, headache, hypokalemia, hypomagnesemia, anemia, renal insufficiency, renal function abnormalities, injection site pain, nausea, vomiting, rigors, and fever.[46] L-AMB therapy has decreased the incidence of renal function abnormalities when compared to AMB-d, yet it still carries a risk of nephrotoxicity. The most common adverse events caused by L-AMB therapy include hypertension, hypotension, tachycardia, localized phlebitis, chills, headache, skin rash, electrolyte abnormalities (hypokalemia, hypomagnesemia, hyponatremia), hyperglycemia, and abnormal liver function tests. ABLC also carries a risk of nephrotoxicity, leading to increased serum creatinine, fever related to infusion, rigors, and chills; however, these risks are less than those associated with treatment regimens, including AMB-d.
Nystatin is approved only for topical and oral "swish-and-swallow" applications due to the potential for severe systemic adverse effects. Adverse events related to topical nystatin include mild contact dermatitis, with the most severe adverse effect being Stevens-Johnson syndrome. Oral "swish-and-swallow" nystatin carries a lower risk of hypersensitivity reactions than topical formulations; there are also reports of diarrhea, nausea, vomiting, and abdominal pain.
Azoles, while typically well-tolerated, frequently cause nausea, vomiting, diarrhea, and abdominal pain. Hepatotoxicity (elevated liver function tests, hepatitis, cholestasis, and or fulminant liver failure) is a common adverse reaction associated with all azoles. Each of the azole drugs has unique adverse events as well:
- Ketoconazole is associated with orthostatic hypotension, thrombocytopenia, pruritis, rash, myalgias, and a rare suppression of glucocorticoid production in the adrenal glands. Of note, ketoconazole also correlates with significantly more gastrointestinal distress than other azoles.
- Fluconazole has been shown to cause mild headaches, dizziness, and alopecia in high doses.[47]
- Itraconazole has a triad of heart failure-like symptoms, hypertension, peripheral edema, and hypokalemia. There are reports of an increased risk of herpes zoster activation or reactivation, headache, dizziness, and fatigue.
- Voriconazole has the most numerous and unique adverse effects in the azole class. These include vision changes, auditory and/or visual hallucinations, neurotoxicity, photosensitivity rash, photophobia, periostitis, cardiotoxicity, and alopecia.
- Posaconazole most commonly causes thrombophlebitis secondary to peripheral intravenous catheters, hypertension, hypotension, headache, rash, hypokalemia, and thrombocytopenia. Another reported adverse event is a rare prolongation of the QTc interval.[48]
- Isavuconazole has more severe gastrointestinal adverse effects than most of the other azoles. Other reported adverse events include a headache, hypokalemia, dyspnea, cough, and peripheral edema.
- Miconazole has no reported serious adverse events; however, it commonly causes contact dermatitis, burning, stinging, and pruritus at the application site.
- Clotrimazole has no severe adverse reactions but commonly causes irritation, burning, or stinging, pruritus, urticaria, and possible blistering at the application site.
Terbinafine, an allylamine, most commonly results in central nervous system adverse effects, with a headache being the most frequently reported symptom. Other manifestations of adverse events include rashes, diarrhea, dyspepsia, and upper respiratory inflammation or infection.
Echinocandins, like many other antifungal agents, can cause hepatotoxicity.
- Anidulafungin is associated with hypotension, peripheral edema, insomnia, hypokalemia, hypomagnesemia, increased risk of urinary tract infections, dyspnea, and fever.
- Caspofungin can cause hypotension, peripheral edema, tachycardia, chills, headache, rash, anemia, localized phlebitis, respiratory failure, and infusion-related reactions.
- Micafungin can cause phlebitis, anemia, transaminitis, hyperbilirubinemia, renal failure, and fever.
- Rezafungin can cause hypomagnesemia, vomiting, hypokalemia, diarrhea, pyrexia, abdominal pain, constipation, anemia, hypophosphatemia, and hepatotoxicity.[49]
Griseofulvin has numerous potential adverse events, with the most commonly reported adverse events being rash and urticaria. More severe complications can occur and include an erythema multiforme-like drug reaction, skin photosensitivity, leukopenia (rare), granulocytopenia, and hepatotoxicity.
Flucytosine can cause adverse reactions to all body systems but is most commonly associated with the following: cardiovascular (cardiotoxicity, chest pain), central and peripheral nervous systems (confusion, headache hallucination, parkinsonian-like syndrome, peripheral neuropathy), dermatologic (pruritis, urticaria, rash), gastrointestinal (abdominal pain, nausea, vomiting, GI hemorrhage), hematologic (agranulocytosis, aplastic anemia, pancytopenia, eosinophilia), hepatic (acute hepatic injury/insufficiency/necrosis), and renal (acute kidney injury, renal failure).
Ciclopirox has no significant associated severe adverse reactions; however, common benign reactions include skin irritation, burning, contact dermatitis, and pruritus.
Quinolines (clioquinol and iodoquinol) are most commonly associated with dry skin, contact dermatitis, allergic reactions, rapid hair growth in areas where the agent is applied, and folliculitis.
Potassium iodide (as a saturated solution of potassium iodide) has several reported severe adverse reactions, including arrhythmias, GI bleeding, angioedema, parotitis, thyroid adenoma, and goiter. More frequent and less severe reactions include a possible metallic taste, urticaria, acne, cutaneous hemorrhage, numbness, and paresthesias.
Zinc pyrithione has no reported serious adverse reactions and most commonly can cause mild skin irritation.
Contraindications
Amphotericin B: All formulations (AMB-d, L-AMB, ABLC, and ABCD) are contraindicated for patients with a known or likely hypersensitivity to amphotericin B or any components of the L-AMB, ABLC, or ABCD formulations.
- AMB-d carries 2 FDA boxed warnings: 1) amphotericin B deoxycholate should be used for invasive, potentially life-threatening mycoses and avoided in non-invasive fungal infections (oral thrush, esophageal candidiasis, and vaginal candidiasis in patients with neutrophil counts within normal limits); 2) risk of accidental overdose. The use of this agent should also exercise extreme caution in patients with renal impairment and or electrolyte abnormalities.
- L-AMB, ABLC, and ABCD do not carry FDA boxed warnings; however, they require caution when administered to patients with renal impairment.
Nystatin is contraindicated for patients with hypersensitivity to the drug or any additional components in the dosage formulation.
Azoles: All should be avoided in patients with hypersensitivity to azole drugs or components of the dosage form, and used with caution in patients with renal impairment or failure, or hepatic impairment or failure.
- Fluconazole requires cautious administration in patients with electrolyte abnormalities, torsades de pointes, and or medical history, family history, or current QTc prolongation.
- Itraconazole has an FDA boxed warning against the use in treating onychomycosis in patients with CHF. Itraconazole is contraindicated in pregnancy, left ventricular dysfunction, and current or active congestive heart failure. This drug should be used cautiously in patients with cystic fibrosis, cardiovascular disease, pulmonary disease, and older adults.
- Ketoconazole carries several FDA boxed warnings:
- This agent should be used only when another effective antifungal, such as azoles, cannot be tolerated or is unavailable.
- This agent carries a significant risk of hepatotoxicity, even in patients without predisposing factors, and thus, any treatment with ketoconazole should include close liver function monitoring.
- Ketoconazole is a cytochrome P450 inhibitor. It has several contraindications for coadministration with drugs that result in QTc prolongation, as it causes increasing concentrations of cisapride, disopyramide, dofetilide, dronedarone, methadone, quinidine, or ranolazine.
- Voriconazole oral formulation is contraindicated in galactose malabsorption/intolerance, lactase deficiency, glucose malabsorption, uncorrected electrolyte abnormalities, and pregnancy. Clinicians should use this agent with caution in patients with a medical or family history of QTc prolongation, history of torsades de pointes, and or hematologic malignancy.
- Isavuconazole is contraindicated in patients with familial short QTc syndrome and should be used with caution in patients with hematologic malignancies.
- Posaconazole is contraindicated in pregnancy. Caution is advisable in patients with electrolyte abnormalities; renal insufficiency; cardiomyopathy; torsades de pointes; or a medical history, family history, or congenital prolonged QTc interval.
Terbinafine should be utilized with caution or avoided in patients with hypersensitivity reactions, depression, gastrointestinal issues, liver failure, and immune suppression secondary to hematologic effects.
All echinocandins are contraindicated in patients with a history of hypersensitivity to any echinocandin drug or its components. Caspofungin should be used with caution in hepatic impairment.
Treatment with griseofulvin should include consideration of potential adverse events in susceptible patients and those with existing disease states, particularly patients with a history of hypersensitivity to griseofulvin, hypersensitivity to penicillins (due to a possible cross-reaction between penicillins and griseofulvin), hepatic failure, known porphyrias, and pregnant or nursing patients.
Flucytosine carries an FDA boxed warning that it should be used with extreme caution in patients with renal impairment, and hematologic, hepatic, and renal function should be closely monitored. This agent is contraindicated in patients with hypersensitivity to this drug or its components, first-trimester pregnancies, and breastfeeding women. Caution is advisable with this agent in patients with renal impairment, hepatic impairment, bone marrow depression, and pregnant patients in their second or third trimester.
The quinolines iodoquinol and clioquinol are contraindicated in patients with hypersensitivities to the drugs or their components.
Antifungals, including ciclopirox, potassium iodide, and zinc pyrithione, are used only as topical agents and should be avoided in patients with hypersensitivities to them.
Monitoring
Polyenes lack supporting evidence or indications to justify the use of therapeutic drug level monitoring (TDM) in patients treated with AMB-d, L-AMB, and ABLC.[50] All patients receiving amphotericin B formulations should have their BUN and creatinine levels assessed at baseline and then monitored frequently; additionally, CBC, electrolytes, and LFTs should be monitored regularly. Nystatin does not have supporting evidence for TDM or routine laboratory monitoring.
Azole antifungals, which are generally indicated for therapeutic drug concentration monitoring (TDM), all belong to the triazole subclass. These include itraconazole, voriconazole, and posaconazole.[50] Laboratory monitoring is necessary for the use of fluconazole, isavuconazonium sulfate, and ketoconazole; however, there is no current indication for monitoring with clotrimazole or miconazole.
- Patients receiving itraconazole should receive TDM. Therapeutic drug concentrations range from 0.5 to 1 μg/mL. Trough concentrations should be assessed after the first administration, around the steady-state time (approximately 5 to 7 days), and reassessed before each consecutive dose. Adverse reactions are more likely to occur if concentrations exceed 5 μg/mL. Additionally, LFTs should undergo an assessment at baseline and be periodically evaluated in patients with hepatic impairment or treatment regimens lasting longer than one month.
- Therapeutic drug concentrations in voriconazole-containing regimens are recommended to be between 1 and 1.5 μg/mL; this requires assessment at the time of steady-state (which varies, approximately 4 to 7 days) and before subsequent administrations. Toxic concentrations are concentrations greater than 5 μg/mL, at which CNS toxicity tends to occur. Monitoring includes LFTs, creatinine, and electrolytes (including magnesium and calcium) at baseline, and LFT levels are frequently checked after that (every week for 4 weeks, then once every 4 weeks thereafter). Lipase should be assessed if a patient is at risk of pancreatitis. Finally, an ophthalmic examination is necessary for patients receiving voriconazole for more than 28 days.
- Posaconazole is administered to achieve therapeutic drug concentrations of greater than 0.7 μg/mL in prophylaxis and greater than 1.0 μg/mL in salvage therapy. Trough serum concentration should be measured on day 7 and before doses or after dose adjustments. Creatinine, electrolytes (including magnesium and calcium), and LFTs should be checked at baseline and then frequently during treatment.
- Monitoring parameters for fluconazole entail checking creatinine at baseline and monitoring LFTs.
- Administering isavuconazonium sulfate requires checking LFTs and baseline, then periodically during treatment.
- Monitoring of ketoconazole-containing regimens should include LFTs at baseline and during therapy, with ALT checked weekly. If the patient is at risk of adrenal insufficiency, their adrenal function should be monitored.
Terbinafine has no supporting evidence to suggest that TDM is necessary for its utilization in prophylaxis, treatment, or toxicity. Monitoring creatinine and LFTs is, however, a baseline indication. Immunodeficient patients receiving terbinafine for longer than 6 weeks should have a CBC checked.
Griseofulvin does not have supporting evidence for TDM, but laboratory monitoring includes BUN, creatinine, CBC, and LFTs.
Patients on echinocandin therapy should be regularly monitored for hepatotoxicity via measurement of hepatic aminotransferases (AST, ALT), with consideration also given to alkaline phosphatase. There is currently no supporting evidence for TDM. Micafungin regimens should include routine laboratory monitoring of BUN and creatinine.
Patients receiving flucytosine-containing combination therapy require TDM. Patients should have serum concentration measured 2 to 4 hours after each dose; the trough concentration should be between 20 and 40 μg/L (some sources state 50 to 100 μg/mL). Toxic concentrations occur when serum drug concentrations exceed 100 μg/mL. Other indications for TDM in flucytosine therapy include when a drug with a known drug interaction is started or stopped, when adherence for oral therapy is uncertain, or when manifestations of toxicity occur.[50]
Enhancing Healthcare Team Outcomes
Pragmatic management of mycoses is dependent on the interprofessional healthcare team characterizing the fungal infection as discussed in the introduction, then selecting the most effective antifungal treatment regimen; this requires a strong understanding of public health/epidemiology, medical microbiology/mycology, clinical pharmacology, and healthcare infrastructure which dictates the application of the first 3. There is currently a diverse and effective arsenal of antifungal agents. Still, the alarming global rise in drug-resistant fungi warrants judicious antifungal prescribing by clinicians, the development of combinatorial strategies, the utilization of antifungal adjuvants, and continued antifungal drug discovery and development.
Judicious prescribing begins with the healthcare team selecting the proper regimen based on culture and sensitivity data, patient history, and socioeconomic factors. Providers should work closely with pharmacists and, when appropriate, public health officials to provide therapy that appropriately treats infections. Nurses can also assess patient adherence, help administer the drug in the inpatient setting, answer patient questions, and monitor for adverse drug reactions. The ultimate goal is to provide antifungal therapy without unnecessarily creating drug-resistant organisms, limiting adverse events, and reducing drug-drug interactions. Antifungal stewardship is crucial for preserving the effectiveness of current antifungal agents.[51]
Combination therapy comprises treatment regimens that incorporate multiple antifungals from different classes and antifungal agents combined with non-antifungal agents. Non-antifungal drug targets include heat shock proteins, calcineurin, lysine acetyltransferase, lysine deacetylase, protein kinase C, and fungal sphingolipids.[52]
Antifungal adjuvants can enhance or extend the efficacy of existing antifungal regimens and limit resistance. Some of these encouraging adjuvants could eventually be the standard of care in antifungal-adjuvant combination therapy. The potential adjuvants include drugs with widely variable mechanisms of action, like cyclosporin A, deferasirox, FK506, tamoxifen, and sertraline.[53]
Antifungal drug discovery has been bolstered by the Orphan Drug Act (1983) and, more recently, the Generating Antibiotic Incentives Now (GAIN) Act (2012). These policies incentivize pharmaceutical companies and researchers to pursue new leads and expand the existing collection of antifungals. The increasing prevalence of drug-resistant fungal diseases presents a significant challenge to the discovery of antifungal drugs. Yet, there are several promising new drugs and class pipelines, theoretical fungal vaccines, and opportunities to generate compounds that inhibit resistance.[54][55][56]
The caveat to all of these potentially promising leads in new drugs and drug classes is the time it takes from discovery to dispensing a new medication, estimated to be roughly 12 years.[57] Unfortunately, this cycle leads to the need for ancillary and interim solutions, which include judicious prescribing to limit resistance, combinatorial therapy, and antifungal adjuvant therapies.
References
Baron S, Walsh TJ, Dixon DM. Spectrum of Mycoses. Medical Microbiology. 1996:(): [PubMed PMID: 21413276]
Lai CC, Tan CK, Huang YT, Shao PL, Hsueh PR. Current challenges in the management of invasive fungal infections. Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 2008 Apr:14(2):77-85. doi: 10.1007/s10156-007-0595-7. Epub 2008 Apr 30 [PubMed PMID: 18622668]
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (London, England). 2009 Feb 20:23(4):525-30. doi: 10.1097/QAD.0b013e328322ffac. Epub [PubMed PMID: 19182676]
Lewis RE. Current concepts in antifungal pharmacology. Mayo Clinic proceedings. 2011 Aug:86(8):805-17. doi: 10.4065/mcp.2011.0247. Epub [PubMed PMID: 21803962]
Phillips NA, Rocktashel M, Merjanian L. Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. Drug design, development and therapy. 2023:17():363-367. doi: 10.2147/DDDT.S339349. Epub 2023 Feb 7 [PubMed PMID: 36785761]
Wang S, Pan J, Gu L, Wang W, Wei B, Zhang H, Chen J, Wang H. Review of treatment options for a multidrug-resistant fungus: Candida auris. Medical mycology. 2024 Jan 9:62(1):. pii: myad127. doi: 10.1093/mmy/myad127. Epub [PubMed PMID: 38066698]
Grover ND. Echinocandins: A ray of hope in antifungal drug therapy. Indian journal of pharmacology. 2010 Feb:42(1):9-11. doi: 10.4103/0253-7613.62396. Epub [PubMed PMID: 20606829]
Fosses Vuong M, Hollingshead CM, Waymack JR. Aspergillosis. StatPearls. 2025 Jan:(): [PubMed PMID: 29489184]
Mada PK, Jamil RT, Alam MU. Cryptococcus. StatPearls. 2025 Jan:(): [PubMed PMID: 28613714]
Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. BioMed research international. 2013:2013():204237. doi: 10.1155/2013/204237. Epub 2013 Jun 26 [PubMed PMID: 23878798]
Miceli A, Krishnamurthy K. Blastomycosis. StatPearls. 2025 Jan:(): [PubMed PMID: 28723016]
Karray M, McKinney WP. Tinea Versicolor. StatPearls. 2025 Jan:(): [PubMed PMID: 29494106]
Akram SM, Koirala J. Coccidioidomycosis. StatPearls. 2025 Jan:(): [PubMed PMID: 28846274]
Nucci F, Nouér SA, Capone D, Anaissie E, Nucci M. Fusariosis. Seminars in respiratory and critical care medicine. 2015 Oct:36(5):706-14. doi: 10.1055/s-0035-1562897. Epub 2015 Sep 23 [PubMed PMID: 26398537]
Akram SM, Koirala J. Histoplasmosis. StatPearls. 2025 Jan:(): [PubMed PMID: 28846361]
Marques SA. Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating. Anais brasileiros de dermatologia. 2013 Sep-Oct:88(5):700-11. doi: 10.1590/abd1806-4841.20132463. Epub [PubMed PMID: 24173174]
Level 2 (mid-level) evidenceKurien G, Sugumar K, Sathe NC, Chandran V. Chromoblastomycosis. StatPearls. 2025 Jan:(): [PubMed PMID: 29261968]
Barros MB, de Almeida Paes R, Schubach AO. Sporothrix schenckii and Sporotrichosis. Clinical microbiology reviews. 2011 Oct:24(4):633-54. doi: 10.1128/CMR.00007-11. Epub [PubMed PMID: 21976602]
Level 3 (low-level) evidenceWeitzman I, Summerbell RC. The dermatophytes. Clinical microbiology reviews. 1995 Apr:8(2):240-59 [PubMed PMID: 7621400]
Šveikauskaitė I, Briedis V. Potential of Naftifine Application for Transungual Delivery. Molecules (Basel, Switzerland). 2020 Jul 3:25(13):. doi: 10.3390/molecules25133043. Epub 2020 Jul 3 [PubMed PMID: 32635240]
Sucher AJ, Thai A, Tran C, Mantena N, Noronha A, Chahine EB. Ibrexafungerp: A new triterpenoid antifungal. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2022 Dec 5:79(24):2208-2221. doi: 10.1093/ajhp/zxac256. Epub [PubMed PMID: 36083109]
Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Mar 1:48(5):503-35. doi: 10.1086/596757. Epub [PubMed PMID: 19191635]
Level 1 (high-level) evidencePerfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010 Feb 1:50(3):291-322. doi: 10.1086/649858. Epub [PubMed PMID: 20047480]
Level 1 (high-level) evidenceWheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, Kauffman CA, Infectious Diseases Society of America. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Oct 1:45(7):807-25 [PubMed PMID: 17806045]
Level 1 (high-level) evidenceChapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA, Infectious Diseases Society of America. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Jun 15:46(12):1801-12. doi: 10.1086/588300. Epub [PubMed PMID: 18462107]
Level 1 (high-level) evidenceKauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Nov 15:45(10):1255-65 [PubMed PMID: 17968818]
Level 1 (high-level) evidenceThursky KA, Playford EG, Seymour JF, Sorrell TC, Ellis DH, Guy SD, Gilroy N, Chu J, Shaw DR. Recommendations for the treatment of established fungal infections. Internal medicine journal. 2008 Jun:38(6b):496-520. doi: 10.1111/j.1445-5994.2008.01725.x. Epub [PubMed PMID: 18588522]
Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, Johnson RH, Kusne S, Lisse J, MacDonald JD, Meyerson SL, Raksin PB, Siever J, Stevens DA, Sunenshine R, Theodore N. 2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Sep 15:63(6):e112-46. doi: 10.1093/cid/ciw360. Epub 2016 Jul 27 [PubMed PMID: 27470238]
Level 1 (high-level) evidencePatterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Aug 15:63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29 [PubMed PMID: 27365388]
Level 1 (high-level) evidenceSahoo AK, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian dermatology online journal. 2016 Mar-Apr:7(2):77-86. doi: 10.4103/2229-5178.178099. Epub [PubMed PMID: 27057486]
Rogers TR. Treatment of zygomycosis: current and new options. The Journal of antimicrobial chemotherapy. 2008 Jan:61 Suppl 1():i35-40. doi: 10.1093/jac/dkm429. Epub [PubMed PMID: 18063603]
Savin R. Diagnosis and treatment of tinea versicolor. The Journal of family practice. 1996 Aug:43(2):127-32 [PubMed PMID: 8708621]
Lortholary O, Fernández-Ruiz M, Perfect JR. The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis). The Journal of antimicrobial chemotherapy. 2016 Nov:71(suppl 2):ii31-ii36 [PubMed PMID: 27880667]
Viecceli C, Mattos ACV, Hirakata VN, Garcia SP, Rodrigues TDC, Czepielewski MA. Ketoconazole as second-line treatment for Cushing's disease after transsphenoidal surgery: systematic review and meta-analysis. Frontiers in endocrinology. 2023:14():1145775. doi: 10.3389/fendo.2023.1145775. Epub 2023 May 8 [PubMed PMID: 37223017]
Level 1 (high-level) evidenceRehman OU, Nadeem ZA, Fatima E, Akram U, Imran H, Husnain A, Nadeem A, Rasheed W. The Efficacy of Ketoconazole Containing Regimens in Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. Clinical genitourinary cancer. 2024 Apr:22(2):483-490.e5. doi: 10.1016/j.clgc.2024.01.003. Epub 2024 Jan 10 [PubMed PMID: 38296679]
Level 1 (high-level) evidenceKhurana A, Sharath S, Sardana K, Chowdhary A, Panesar S. Therapeutic Updates on the Management of Tinea Corporis or Cruris in the Era of Trichophyton Indotineae: Separating Evidence from Hype-A Narrative Review. Indian journal of dermatology. 2023 Sep-Oct:68(5):525-540. doi: 10.4103/ijd.ijd_832_23. Epub [PubMed PMID: 38099117]
Level 3 (low-level) evidencePrasad R, Shah AH, Rawal MK. Antifungals: Mechanism of Action and Drug Resistance. Advances in experimental medicine and biology. 2016:892():327-349. doi: 10.1007/978-3-319-25304-6_14. Epub [PubMed PMID: 26721281]
Level 3 (low-level) evidenceGhannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clinical microbiology reviews. 1999 Oct:12(4):501-17 [PubMed PMID: 10515900]
Level 3 (low-level) evidenceBirnbaum JE. Pharmacology of the allylamines. Journal of the American Academy of Dermatology. 1990 Oct:23(4 Pt 2):782-5 [PubMed PMID: 2229523]
Level 3 (low-level) evidenceElewski BE. Mechanisms of action of systemic antifungal agents. Journal of the American Academy of Dermatology. 1993 May:28(5 Pt 1):S28-S34 [PubMed PMID: 8496409]
Waldorf AR, Polak A. Mechanisms of action of 5-fluorocytosine. Antimicrobial agents and chemotherapy. 1983 Jan:23(1):79-85 [PubMed PMID: 6338821]
Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrobial agents and chemotherapy. 2003 Jun:47(6):1805-17 [PubMed PMID: 12760852]
Hiruma M, Kagawa S. Ultrastructure of Sporothrix schenckii treated with iodine-potassium iodide solution. Mycopathologia. 1987 Feb:97(2):121-7 [PubMed PMID: 3574432]
Chandler CJ, Segel IH. Mechanism of the antimicrobial action of pyrithione: effects on membrane transport, ATP levels, and protein synthesis. Antimicrobial agents and chemotherapy. 1978 Jul:14(1):60-8 [PubMed PMID: 28693]
Reeder NL, Xu J, Youngquist RS, Schwartz JR, Rust RC, Saunders CW. The antifungal mechanism of action of zinc pyrithione. The British journal of dermatology. 2011 Oct:165 Suppl 2():9-12. doi: 10.1111/j.1365-2133.2011.10571.x. Epub [PubMed PMID: 21919897]
Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: side effects and toxicity. Revista iberoamericana de micologia. 2009 Dec 31:26(4):223-7. doi: 10.1016/j.riam.2009.06.003. Epub [PubMed PMID: 19836985]
Level 3 (low-level) evidencePappas PG, Kauffman CA, Perfect J, Johnson PC, McKinsey DS, Bamberger DM, Hamill R, Sharkey PK, Chapman SW, Sobel JD. Alopecia associated with fluconazole therapy. Annals of internal medicine. 1995 Sep 1:123(5):354-7 [PubMed PMID: 7625624]
Level 2 (mid-level) evidenceMohr J, Johnson M, Cooper T, Lewis JS, Ostrosky-Zeichner L. Current options in antifungal pharmacotherapy. Pharmacotherapy. 2008 May:28(5):614-45. doi: 10.1592/phco.28.5.614. Epub [PubMed PMID: 18447660]
Al Shaer D, Al Musaimi O, Albericio F, de la Torre BG. 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest. Pharmaceuticals (Basel, Switzerland). 2024 Feb 13:17(2):. doi: 10.3390/ph17020243. Epub 2024 Feb 13 [PubMed PMID: 38399458]
Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. The Journal of antimicrobial chemotherapy. 2014 May:69(5):1162-76. doi: 10.1093/jac/dkt508. Epub 2013 Dec 29 [PubMed PMID: 24379304]
Richardson MD. An introduction to antifungal stewardship. The Journal of antimicrobial chemotherapy. 2016 Nov:71(suppl 2):ii3 [PubMed PMID: 27880663]
Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence. 2017 Feb 17:8(2):169-185. doi: 10.1080/21505594.2016.1196300. Epub 2016 Jun 7 [PubMed PMID: 27268286]
Butts A, Palmer GE, Rogers PD. Antifungal adjuvants: Preserving and extending the antifungal arsenal. Virulence. 2017 Feb 17:8(2):198-210. doi: 10.1080/21505594.2016.1216283. Epub 2016 Jul 26 [PubMed PMID: 27459018]
Calderone R, Sun N, Gay-Andrieu F, Groutas W, Weerawarna P, Prasad S, Alex D, Li D. Antifungal drug discovery: the process and outcomes. Future microbiology. 2014:9(6):791-805. doi: 10.2217/fmb.14.32. Epub [PubMed PMID: 25046525]
Jampilek J. How can we bolster the antifungal drug discovery pipeline? Future medicinal chemistry. 2016 Aug:8(12):1393-7. doi: 10.4155/fmc-2016-0124. Epub 2016 Jul 27 [PubMed PMID: 27464242]
Reales-Calderón JA, Molero G, Gil C, Martínez JL. The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies. Future medicinal chemistry. 2016 Aug:8(12):1503-20. doi: 10.4155/fmc-2016-0051. Epub 2016 Aug 3 [PubMed PMID: 27485839]
Butts A, Krysan DJ. Antifungal drug discovery: something old and something new. PLoS pathogens. 2012 Sep:8(9):e1002870. doi: 10.1371/journal.ppat.1002870. Epub 2012 Sep 6 [PubMed PMID: 22969422]